| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Ceritinib impurity 5 does not have a defined biological target as it is an inactive impurity. The parent drug ceritinib is a potent ALK (anaplastic lymphoma kinase) inhibitor, used for ALK-positive non-small cell lung cancer. This impurity is not intended for pharmacological studies; it serves only as an analytical standard for quality control. [3L13-L15]
|
|---|---|
| ln Vitro |
Ceritinib impurity 5 has no reported in vitro biological activity. It is not tested for ALK inhibition. Its sole purpose is as a chemical reference material for analytical quality control. The impurity is used to prepare calibration standards for HPLC or LC-MS/MS to quantify its levels in ceritinib batches. No cell-based assays are performed. [3L13-L15]
|
| ln Vivo |
No in vivo activity data are available for Ceritinib impurity 5. It is not administered to animals for efficacy studies. The compound is used exclusively as a reference standard in chemical analysis. Its presence in ceritinib drug substance is controlled at low levels (typically <0.1-0.5%) to ensure safety and compliance. For research use only. [3L8-L10]
|
| Enzyme Assay |
Not applicable. Ceritinib impurity 5 is an analytical reference standard. For non-cellular characterization, a standard HPLC method is used: dissolve the compound in methanol or acetonitrile to 0.5 mg/mL. Inject onto a C18 column (250×4.6 mm, 5 microm). Mobile phase: 0.1% formic acid in water (A) and acetonitrile (B). Gradient: 25% B to 85% B over 25 min. UV detection at 254 nm. For LC-MS/MS, positive ESI mode, m/z 558 [M+H]+. Purity >95% by HPLC. No enzyme assays. [3L8-L10]
|
| Cell Assay |
Not applicable. Ceritinib impurity 5 is not used in cell-based biological assays. It is a chemical reference standard for analytical quality control. For cell culture studies, the parent drug ceritinib would be used, but not this impurity. For research use only. [3L13-L15]
|
| Animal Protocol |
Not applicable. Ceritinib impurity 5 is not used for in vivo animal studies. It is a reference standard for chemical analysis. No animal dosing or efficacy studies are performed. For research use only. [3L8-L10]
|
| ADME/Pharmacokinetics |
Not applicable. Ceritinib impurity 5 is a pharmaceutical impurity, not a drug candidate; its pharmacokinetic properties are not characterized. For storage, powder at -20degC for up to 3 years, protected from light and moisture. Solubility: DMSO, methanol. Appearance: solid powder. Purity >95% by HPLC. [3L8-L10]
|
| Toxicity/Toxicokinetics |
No toxicity data are available for Ceritinib impurity 5 as a pure compound. In pharmaceutical manufacturing, the allowable limit of this impurity is controlled based on ICH guidelines (≤0.1-0.5%). Standard lab safety: avoid inhalation, ingestion, skin/eye contact; use PPE; work in a fume hood. For research only-not for human use. [3L13-L15]
|
| Additional Infomation |
CAS: 1260864-79-6. Molecular formula: C2₈H3₆ClN₅O3S, molecular weight: 558.14. Also known as Ceritinib Impurity 5. Purity: >95% by HPLC. Appearance: solid powder. Storage: -20degC. Use: pharmaceutical reference standard. Not for human use. For research only. [3L4-L7][3L16-L18]
|
| Molecular Formula |
C12H18N2
|
|---|---|
| Molecular Weight |
190.29
|
| CAS # |
1260864-79-6
|
| Related CAS # |
Ceritinib impurity 5
|
| Appearance |
Solid powder
|
| Synonyms |
Ceritinib impurity 55
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2551 mL | 26.2757 mL | 52.5514 mL | |
| 5 mM | 1.0510 mL | 5.2551 mL | 10.5103 mL | |
| 10 mM | 0.5255 mL | 2.6276 mL | 5.2551 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
